Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma

Oncotarget

Volumn 7, Issue 3, 2016, Pages 3520-3532

  Dupont, Thibault ^a   Yang, ShaoNing ^a   Patel, Jayeshkumar ^a   Hatzi, Katerina ^a   Malik, Alka ^a   Tam, Wayne ^a   Martin, Peter ^a   Leonard, John ^a   Melnick, Ari ^a   Cerchietti, Leandro ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

BCL2; BCL6; Lymphoma; Resistance; Targeting

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; BORTEZOMIB; OBATOCLAX; PEVONEDISTAT; PROTEASOME; PROTEIN BCL 2; PROTEIN BCL 6; RI BPI PEPTIDE; UNCLASSIFIED DRUG; ABT-737; BAX PROTEIN (53-86); BCL2 PROTEIN, HUMAN; BCL6 PROTEIN, HUMAN; BIPHENYL DERIVATIVE; NITROPHENOL; ONCOPROTEIN; PEPTIDE FRAGMENT; PIPERAZINE DERIVATIVE; PYRROLE DERIVATIVE; SMALL INTERFERING RNA; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; LARGE CELL LYMPHOMA; MALE; MOUSE; NONHUMAN; ONCOGENE ADDICTION SWITCHING; ONCOLOGICAL PARAMETERS; PROTEIN FUNCTION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETICS; HUMAN; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; NUDE MOUSE; PATHOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICE; MICE, NUDE; NITROPHENOLS; PEPTIDE FRAGMENTS; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-BCL-6; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; SULFONAMIDES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962263699     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6513     Document Type: Article

References (34)

1. Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF and Melnick A. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood. 2009; 113:3397-3405.
2. Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Fares C, Arrowsmith CH, Yang SN, Garcia M, Coop A, Mackerell AD, Jr., Prive GG and Melnick A. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer cell. 2010; 17:400-411.
3. Cerchietti L and Melnick A. Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment? Expert review of hematology. 2013; 6:343-345.
4. Klein U and Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nature reviews Immunology. 2008; 8:22-33.
5. Lenz G and Staudt LM. Aggressive lymphomas. N Engl J Med. 2010; 362:1417-1429.
6. Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF and Melnick A. Sequential transcription factor targeting for diffuse large B-cell lymphomas. Cancer Res. 2008; 68:3361-3369.
7. Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, Ye K, Farinha P, Horsman DE, Gascoyne RD, Elemento O and Melnick A. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 2009; 113:5536-5548.
8. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011; 473:384-388.
9. Li Z, Wang X, Yu RY, Ding BB, Yu JJ, Dai XM, Naganuma A, Stanley ER and Ye BH. BCL-6 negatively regulates expression of the NF-kappaB1 p105/p50 subunit. Journal of immunology. 2005; 174:205-214.
10. Hatzi K and Melnick A. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends in molecular medicine. 2014; 20:343-352.
11. Saito M, Novak U, Piovan E, Basso K, Sumazin P, Schneider C, Crespo M, Shen Q, Bhagat G, Califano A, Chadburn A, Pasqualucci L and Dalla-Favera R. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2009; 106:11294-11299.
12. Chandarlapaty S. Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer discovery. 2012; 2:311-319.
13. Bergers G and Hanahan D. Modes of resistance to antiangiogenic therapy. Nature reviews Cancer. 2008; 8:592-603.
14. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M and Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007; 12:171-185.
15. Merino D, Strasser A and Bouillet P. Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression. Oncogene. 2012; 31:3392-3396.
16. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, Shehata S, Kung AL, Beroukhim R and Golub TR. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer cell. 2012; 21:547-562.
17. Goldsmith KC, Gross M, Peirce S, Luyindula D, Liu X, Vu A, Sliozberg M, Guo R, Zhao H, Reynolds CP and Hogarty MD. Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res. 2012; 72:2565-2577.
18. Rooswinkel RW, van de Kooij B, Verheij M and Borst J. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell death & disease. 2012; 3:e366.
19. Besbes S, Mirshahi M, Pocard M and Billard C. New dimension in therapeutic targeting of BCL-2 family proteins. Oncotarget. 2015; 6:12862-12871. doi: 10.18632/oncotarget.3868.
20. Fennell DA, Chacko A and Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene. 2008; 27:1189-1197.
21. Dengler MA, Weilbacher A, Gutekunst M, Staiger AM, Vohringer MC, Horn H, Ott G, Aulitzky WE and van der Kuip H. Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma. Cell death & disease. 2014; 5:e1013.
22. Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MH and Eldering E. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:487-498.
23. Ohshima-Hosoyama S, Davare MA, Hosoyama T, Nelon LD and Keller C. Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma. Journal of neuro-oncology. 2011; 105:475-483.
24. Knorr KL, Schneider PA, Meng XW, Dai H, Smith BD, Hess AD, Karp JE and Kaufmann SH. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. Cell death and differentiation. 2015.
25. Li L, Wang M, Yu G, Chen P, Li H, Wei D, Zhu J, Xie L, Jia H, Shi J, Li C, Yao W, Wang Y, Gao Q, Jeong LS, Lee HW, et al. Overactivated neddylation pathway as a therapeutic target in lung cancer. Journal of the National Cancer Institute. 2014; 106:dju083.
26. Rizzatti EG, Mora-Jensen H, Weniger MA, Gibellini F, Lee E, Daibata M, Lai R and Wiestner A. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leukemia & lymphoma. 2008; 49:798-808.
27. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP, Manfredi M, Narayanan U, Rolfe M, Staudt LM, Soucy TA, Yu J, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB-dependent lymphoma. Blood. 2010; 116:1515-1523.
28. Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P and Grant S. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC-and ABC-DLBCL cells in vitro and in vivo. Molecular cancer therapeutics. 2012; 11:1122-1132.
29. Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K and O'Connor OA. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood. 2008; 112:2906-2916.
30. Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D and Anderson KC. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. British journal of haematology. 2006; 134:145-156.
31. Tianhu Z, Shiguang Z and Xinghan L. Bmf is upregulated by PS-341-mediated cell death of glioma cells through JNK phosphorylation. Mol Biol Rep. 2010; 37:1211-1219.
32. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Belec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A. 2007; 104:19512-19517.
33. Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J, Green R, Carroll M and Melnick A. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nature immunology. 2007; 8:705-714.
34. Wenzel SS, Grau M, Mavis C, Hailfinger S, Wolf A, Madle H, Deeb G, Dorken B, Thome M, Lenz P, Dirnhofer S, Hernandez-Ilizaliturri FJ, Tzankov A and Lenz G. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia. 2013; 27:1381-1390.